Company intelligence / Profile preview

FIRE1

Ownership: Private
Employees: ~62
Development stage: Phase 1

Overview

FIRE1’s Norm system is an investigational implantable device for remote monitoring of heart failure patients. It enables daily at-home tracking of fluid volume status, aiming to empower patient self-management and reduce hospitalizations. The system has received FDA Breakthrough Device Designation and is currently being evaluated in pivotal clinical trials, including the FUTURE-HF first-in-human study expanded to Ireland in 2024. No commercial or late-stage results have been published yet.

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital health solution (remote monitoring)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Norm

Phase 1

Indications: Heart failure

Partnerships

Medtronic (investor/backer)

Beyond the preview

Go deeper on FIRE1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIRE1.

Explore the full profile